The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy.
Recent studies demonstrate that, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers may decrease left ventricular hypertrophy (LVH) in hypertensive patients. We wanted to assess the efficacy of valsartan on echocardiographic variables of LVH in 30 mild to moderate hypertensive patients. Valsartan was found effective in controlling hypertension, also echocardiographic indices of LVH such as interventricular septum and posterior wall thickness were reduced and left ventricular mass decreased significantly. Thus valsartan favorably influences cardiac structure in hypertensive patients.
Mutlu
Haşim
H
Istanbul University, Institute of Cardiology, Turkey. hasimmutlu@hotmail.com
Ozhan
Hakan
H
Okçün
Bariş
B
Okuyan
Ertugrul
E
Yigit
Zerrin
Z
Erbaş
Cennet
C
Küçükoglu
M Serdar
MS
Gültekin
Nazmi
N
Uner
Sinan
S
Erdine
Serap
S
Güven
Ozen
O
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D015331:Cohort Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000473:pathology; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D013777:Tetrazoles / Q000008:administration & dosage* / Q000494:pharmacology; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D014463:Ultrasonography; D014633:Valine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
D000806:Angiotensin-Converting Enzyme Inhibitors; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine